Uncategorized

Vertex unfazed by competitive IgAN space as FDA verdict looms

Published

on

Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said on the company’s second quarter earnings call.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version